bupropion has been researched along with Bipolar Disorder in 87 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
Bipolar Disorder: A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "US Clinical Trials registration was systematically searched for studies examining the effects of dextromethorphan in mood disorders." | 9.41 | Combinations of dextromethorphan for the treatment of mood disorders - a review of the evidence. ( Iosifescu, DV; Parincu, Z, 2023) |
| "Bupropion was added to the treatment regimens of 3 male and 8 female patients who had bipolar disorders as diagnosed by DSM-III-R criteria and were depressed and nonresponsive to current treatment." | 9.07 | Bupropion in the treatment of bipolar disorders: the same old story? ( Bystritsky, A; Fogelson, DL; Pasnau, R, 1992) |
| "Bupropion is widely used for treating bipolar disorder (BD), and especially those with depressive mood, based on its good treatment effect, safety profile, and lower risk of phase shifting." | 8.93 | Significant Treatment Effect of Bupropion in Patients With Bipolar Disorder but Similar Phase-Shifting Rate as Other Antidepressants: A Meta-Analysis Following the PRISMA Guidelines. ( Chen, YW; Li, DJ; Lin, PY; Tseng, PT; Wu, CK, 2016) |
| "One randomised controlled trial met the inclusion criteria for the review, a comparison between topiramate and bupropion sustained release (SR) in the adjunctive treatment of depressed patients with bipolar disorder." | 8.83 | Topiramate for acute affective episodes in bipolar disorder. ( Geddes, J; Macritchie, K; Vasudev, K; Watson, S; Young, A, 2006) |
| "Agents effective against mania in bipolar disorder are reported to decrease turnover of arachidonic acid (AA) in phospholipids and expression of calcium-dependent AA-selective cytosolic phospholipase A(2) (cPLA(2)) in rat brain." | 7.76 | Chronic imipramine but not bupropion increases arachidonic acid signaling in rat brain: is this related to 'switching' in bipolar disorder? ( Chang, L; Kim, HW; Lee, HJ; Rao, JS; Rapoport, SI, 2010) |
| "Bupropion was associated with reductions in ratings of mania and depression." | 6.71 | An open trial of bupropion for the treatment of adults with attention-deficit/hyperactivity disorder and bipolar disorder. ( Biederman, J; Brown, S; Doyle, R; Girard, K; Goldman, S; Hammerness, P; Prince, JB; Spencer, T; Van Patten, SL; Wilens, TE, 2003) |
| "US Clinical Trials registration was systematically searched for studies examining the effects of dextromethorphan in mood disorders." | 5.41 | Combinations of dextromethorphan for the treatment of mood disorders - a review of the evidence. ( Iosifescu, DV; Parincu, Z, 2023) |
| "Bupropion (BUP) may be less likely than other antidepressants to cause switches into mania and rapid cycling, suggesting utility in bipolar disorder." | 5.08 | Carbamazepine but not valproate induces bupropion metabolism. ( Callahan, AM; Chao, J; George, MS; Hinton, ML; Jenkins, JB; Ketter, TA; Marangell, LB; Pazzaglia, PJ; Post, RM; Schroeder, DH, 1995) |
| "Bupropion was added to the treatment regimens of 3 male and 8 female patients who had bipolar disorders as diagnosed by DSM-III-R criteria and were depressed and nonresponsive to current treatment." | 5.07 | Bupropion in the treatment of bipolar disorders: the same old story? ( Bystritsky, A; Fogelson, DL; Pasnau, R, 1992) |
| "Bupropion is widely used for treating bipolar disorder (BD), and especially those with depressive mood, based on its good treatment effect, safety profile, and lower risk of phase shifting." | 4.93 | Significant Treatment Effect of Bupropion in Patients With Bipolar Disorder but Similar Phase-Shifting Rate as Other Antidepressants: A Meta-Analysis Following the PRISMA Guidelines. ( Chen, YW; Li, DJ; Lin, PY; Tseng, PT; Wu, CK, 2016) |
| "One randomised controlled trial met the inclusion criteria for the review, a comparison between topiramate and bupropion sustained release (SR) in the adjunctive treatment of depressed patients with bipolar disorder." | 4.83 | Topiramate for acute affective episodes in bipolar disorder. ( Geddes, J; Macritchie, K; Vasudev, K; Watson, S; Young, A, 2006) |
| "Lithium is currently the gold standard and most appropriate initial treatment for the depressive phase of bipolar disorder." | 4.80 | The treatment of bipolar depression. ( Compton, MT; Nemeroff, CB, 2000) |
| "Here we report a case of bupropion abuse in a 79-year-old gentleman with a history of alcohol and amphetamine use disorders, resulting in hypertension and hypomanic symptoms." | 3.81 | Bupropion abuse resulting in hypomania in a geriatric amphetamine user: A case report. ( Rostas, A; Wolf, U, 2015) |
| "Agents effective against mania in bipolar disorder are reported to decrease turnover of arachidonic acid (AA) in phospholipids and expression of calcium-dependent AA-selective cytosolic phospholipase A(2) (cPLA(2)) in rat brain." | 3.76 | Chronic imipramine but not bupropion increases arachidonic acid signaling in rat brain: is this related to 'switching' in bipolar disorder? ( Chang, L; Kim, HW; Lee, HJ; Rao, JS; Rapoport, SI, 2010) |
| " Exposure to bupropion during pregnancy (OR = 3." | 3.76 | Use of antidepressants during pregnancy and risk of attention-deficit/hyperactivity disorder in the offspring. ( Figueroa, R, 2010) |
| "Antidepressants are used to treat acute depression in patients with bipolar I disorder, but their effect as maintenance treatment after the remission of depression has not been well studied." | 3.30 | Duration of Adjunctive Antidepressant Maintenance in Bipolar I Depression. ( Ahn, YM; Arumugham, SS; Ashok, MV; Beaulieu, S; Bhandary, RP; Bond, DJ; Daigneault, A; Frey, BN; Ha, K; Kesavan, M; Kondapuram, N; Lam, RW; Milev, R; Murthy, NS; Ouyang, Y; Ramachandran, K; Ravindran, A; Ravindran, N; Reddy, MS; Reddy, YCJ; Saraf, G; Schaffer, A; Wong, H; Yatham, LN, 2023) |
| " Primary outcomes were occurrence of moderate to severe neuropsychiatric adverse events (NPSAEs) and Weeks 9-12 biochemically-confirmed continuous abstinence (CA) rates." | 2.90 | Safety and efficacy of first-line smoking cessation pharmacotherapies in bipolar disorders: Subgroup analysis of a randomized clinical trial. ( Anthenelli, RM; Aubin, LS; Ayers, CR; Evins, AE; Heffner, JL; Krishen, A; Lawrence, D; McRae, T; Russ, C; West, R, 2019) |
| " The allocation to either high- and low-dose antidepressants was not randomized and the dose was guided by a case-by-case decision, which hampers to draw a firm conclusion on dose-response issues and renders the findings as preliminary." | 2.80 | Antidepressant dose and treatment response in bipolar depression: Reanalysis of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) data. ( Mimura, M; Mizushima, J; Nio, S; Suzuki, T; Tada, M; Uchida, H, 2015) |
| "Eighty-three outpatients with DSM-IV bipolar depression who were enrolled between March 1996 and November 2002 and were treated in a 10-week acute double-blind antidepressant treatment trial agreed to participate in a 1-year double-blind continuation of their medication." | 2.74 | Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study. ( Altshuler, LL; Frye, MA; Grunze, H; Hellemann, G; Keck, PE; Kupka, RW; Leverich, GS; McElroy, SL; Nolen, WA; Post, RM; Sugar, CA; Suppes, T, 2009) |
| "The large percentage of adults with major depressive disorder (MDD) insufficiently responding and/or tolerating conventional monoamine-based antidepressants invites the need for mechanistically novel treatments." | 2.72 | Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials. ( Cao, B; Ho, R; Majeed, A; McIntyre, RS; Ng, J; Phan, L; Rosenblat, JD; Teopiz, KM; Xiong, J, 2021) |
| "Bupropion was associated with reductions in ratings of mania and depression." | 2.71 | An open trial of bupropion for the treatment of adults with attention-deficit/hyperactivity disorder and bipolar disorder. ( Biederman, J; Brown, S; Doyle, R; Girard, K; Goldman, S; Hammerness, P; Prince, JB; Spencer, T; Van Patten, SL; Wilens, TE, 2003) |
| "Although treatment of bipolar depression is a frequent clinical problem, double-blind studies of the treatment of bipolar depression are scarce." | 2.67 | A double-blind trial of bupropion versus desipramine for bipolar depression. ( Banov, M; Lafer, B; Rosenbaum, JF; Sachs, GS; Stoll, AL; Thibault, AB; Tohen, M, 1994) |
| " Neonatal providers should be aware of maternal medications and prepare for possible adverse effects, particularly from common psychotropic exposures." | 1.62 | Why the Maternal Medication List Matters: Neonatal Toxicity From Combined Serotonergic Exposures. ( Brajcich, MR; Marks, J; Messer, RD; Murphy, ME; Palau, MA, 2021) |
| "Here we report two cases of bipolar depressionpatients with manic shift when bupropion was used as an adjunct tomood stabilizer treatment." | 1.51 | [Manic Shift Due to the Use of Bupropion in Bipolar Depression:Two Case Reports]. ( Görgülü, Y; Kahyacı Kılıç, E; Köse Çınar, R; Sönmez, MB, 2019) |
| "Bupropion therapy was initiated and the dosage was titrated to 600 mg/d." | 1.31 | Mania with bupropion: a dose-related phenomenon? ( Goren, JL; Levin, GM, 2000) |
| " The experts' antidepressant dose and dosing schedule recommendations are equivalent for unipolar and bipolar depression, but the experts recommend a faster discontinuation of antidepressants during the maintenance phase in bipolar patients--probably to reduce the risk of rapid cycling." | 1.30 | The Expert Consensus Guidelines for treating depression in bipolar disorder. ( Carpenter, D; Docherty, JP; Donovan, SL; Frances, AJ; Kahn, DA, 1998) |
| " Monitering of BUP and its metabolites may ultimately prove useful in guiding clinicians dosing decisions, especially when mood stabilizers are combined with other psychotropic drugs in refractory bipolar patients." | 1.29 | Bupropion and anticonvulsant drug interactions. ( Lamparella, V; Masand, PS; Popli, AP; Tanquary, J, 1995) |
| "Bupropion hydrochloride is a phenylaminoketone antidepressant whose clinical pharmacology is poorly understood." | 1.28 | Organic mental disorders associated with bupropion in three patients. ( Ames, D; Szuba, MP; Wirshing, WC, 1992) |
| "Bupropion was added to lithium and/or levothyroxine in four female and two male bipolar II patients who had established baselines of at least 2 years of rapid cycling that had not responded to several of the most commonly used anticycling interventions." | 1.28 | Bupropion as a promising approach to rapid cycling bipolar II patients. ( Akiskal, HS; Haykal, RF, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (5.75) | 18.7374 |
| 1990's | 25 (28.74) | 18.2507 |
| 2000's | 31 (35.63) | 29.6817 |
| 2010's | 22 (25.29) | 24.3611 |
| 2020's | 4 (4.60) | 2.80 |
| Authors | Studies |
|---|---|
| Parincu, Z | 1 |
| Iosifescu, DV | 1 |
| Yatham, LN | 2 |
| Arumugham, SS | 1 |
| Kesavan, M | 1 |
| Ramachandran, K | 1 |
| Murthy, NS | 1 |
| Saraf, G | 1 |
| Ouyang, Y | 1 |
| Bond, DJ | 2 |
| Schaffer, A | 2 |
| Ravindran, A | 2 |
| Ravindran, N | 1 |
| Frey, BN | 2 |
| Daigneault, A | 1 |
| Beaulieu, S | 2 |
| Lam, RW | 2 |
| Kondapuram, N | 1 |
| Reddy, MS | 1 |
| Bhandary, RP | 1 |
| Ashok, MV | 1 |
| Ha, K | 1 |
| Ahn, YM | 1 |
| Milev, R | 1 |
| Wong, H | 1 |
| Reddy, YCJ | 1 |
| Kahyacı Kılıç, E | 1 |
| Görgülü, Y | 1 |
| Köse Çınar, R | 1 |
| Sönmez, MB | 1 |
| Brajcich, MR | 1 |
| Palau, MA | 1 |
| Messer, RD | 1 |
| Murphy, ME | 1 |
| Marks, J | 1 |
| Majeed, A | 1 |
| Xiong, J | 1 |
| Teopiz, KM | 1 |
| Ng, J | 1 |
| Ho, R | 1 |
| Rosenblat, JD | 1 |
| Phan, L | 1 |
| Cao, B | 1 |
| McIntyre, RS | 3 |
| Chen, PH | 1 |
| Chung, KH | 1 |
| Kennedy, SH | 2 |
| Parikh, SV | 2 |
| Sharma, V | 1 |
| Goldstein, BI | 1 |
| Rej, S | 1 |
| Alda, M | 1 |
| MacQueen, G | 1 |
| Milev, RV | 1 |
| O'Donovan, C | 1 |
| McIntosh, D | 1 |
| Vazquez, G | 1 |
| Kapczinski, F | 1 |
| Kozicky, J | 1 |
| Kanba, S | 1 |
| Lafer, B | 2 |
| Suppes, T | 5 |
| Calabrese, JR | 2 |
| Vieta, E | 1 |
| Malhi, G | 1 |
| Post, RM | 6 |
| Berk, M | 1 |
| Jha, MK | 1 |
| Malchow, AL | 1 |
| Grannemann, BD | 1 |
| Rush, AJ | 2 |
| Trivedi, MH | 1 |
| Yoon, W | 1 |
| Shon, SH | 1 |
| Hong, Y | 1 |
| Joo, YH | 1 |
| Lee, JS | 1 |
| Heffner, JL | 1 |
| Evins, AE | 1 |
| Russ, C | 1 |
| Lawrence, D | 1 |
| Ayers, CR | 1 |
| McRae, T | 1 |
| Aubin, LS | 1 |
| Krishen, A | 1 |
| West, R | 1 |
| Anthenelli, RM | 1 |
| Lu, YY | 1 |
| Hsueh, JH | 1 |
| Wei, IH | 1 |
| Huang, CC | 1 |
| Giasson-Gariépy, K | 1 |
| Jutras-Aswad, D | 1 |
| Garcia-Portilla, MP | 1 |
| Garcia-Alvarez, L | 1 |
| Saiz, PA | 1 |
| Diaz-Mesa, E | 1 |
| Galvan, G | 1 |
| Sarramea, F | 1 |
| Garcia-Blanco, J | 1 |
| Elizagarate, E | 1 |
| Bobes, J | 1 |
| McGinty, EE | 1 |
| Baller, J | 1 |
| Azrin, ST | 1 |
| Juliano-Bult, D | 1 |
| Daumit, GL | 1 |
| Tada, M | 1 |
| Uchida, H | 1 |
| Mizushima, J | 1 |
| Suzuki, T | 1 |
| Mimura, M | 1 |
| Nio, S | 1 |
| Tidey, JW | 1 |
| Miller, ME | 1 |
| Gama Marques, J | 1 |
| Saraiva, S | 1 |
| Brissos, S | 1 |
| Rostas, A | 1 |
| Wolf, U | 1 |
| Fawcett, J | 1 |
| Vukelich, J | 1 |
| Diaz, SH | 1 |
| Dunklee, L | 1 |
| Romo, P | 1 |
| Yarns, BC | 1 |
| Escalona, R | 1 |
| Li, DJ | 1 |
| Tseng, PT | 1 |
| Chen, YW | 1 |
| Wu, CK | 1 |
| Lin, PY | 1 |
| Hussain, H | 1 |
| Butt, MA | 1 |
| Delva, NJ | 1 |
| Weinberger, AH | 1 |
| Vessicchio, JC | 1 |
| Sacco, KA | 1 |
| Creeden, CL | 1 |
| Chengappa, KN | 1 |
| George, TP | 1 |
| Lee, HJ | 1 |
| Rao, JS | 1 |
| Chang, L | 1 |
| Rapoport, SI | 1 |
| Kim, HW | 1 |
| Frye, MA | 4 |
| Helleman, G | 1 |
| McElroy, SL | 3 |
| Altshuler, LL | 4 |
| Black, DO | 1 |
| Keck, PE | 4 |
| Nolen, WA | 4 |
| Kupka, R | 1 |
| Leverich, GS | 4 |
| Grunze, H | 5 |
| Mintz, J | 2 |
| Schroeder, SA | 1 |
| Hellemann, G | 1 |
| Kupka, RW | 3 |
| Sugar, CA | 1 |
| Dervaux, A | 1 |
| Laqueille, X | 1 |
| Nierenberg, AA | 2 |
| Mah, L | 1 |
| Conn, DK | 1 |
| LeBlanc, SR | 1 |
| Ovanessian, MM | 1 |
| Figueroa, R | 1 |
| Schwartz, PJ | 1 |
| Aggarwal, A | 1 |
| Sharma, RC | 1 |
| Mancini, DA | 1 |
| McCann, S | 1 |
| Srinivasan, J | 1 |
| Sagman, D | 1 |
| Baab, SW | 1 |
| Peindl, KS | 1 |
| Piontek, CM | 1 |
| Wisner, KL | 1 |
| Margolese, HC | 1 |
| Beauclair, L | 1 |
| Szkrumelak, N | 1 |
| Chouinard, G | 1 |
| Kowatch, RA | 1 |
| Sethuraman, G | 1 |
| Hume, JH | 1 |
| Kromelis, M | 1 |
| Weinberg, WA | 1 |
| Wilens, TE | 1 |
| Prince, JB | 1 |
| Spencer, T | 1 |
| Van Patten, SL | 1 |
| Doyle, R | 1 |
| Girard, K | 1 |
| Hammerness, P | 1 |
| Goldman, S | 1 |
| Brown, S | 1 |
| Biederman, J | 1 |
| Dell, DL | 1 |
| O'Brien, BW | 1 |
| Michael, N | 2 |
| Erfurth, A | 2 |
| Bergant, V | 1 |
| Bagley, SC | 1 |
| Yaeger, D | 1 |
| Tesar, GE | 1 |
| Vasudev, K | 1 |
| Macritchie, K | 1 |
| Geddes, J | 1 |
| Watson, S | 1 |
| Young, A | 1 |
| Denicoff, KD | 2 |
| Martinez, MI | 1 |
| Papakostas, GI | 1 |
| Petersen, TJ | 1 |
| Perlis, RH | 1 |
| Judy, AE | 1 |
| Burns, AM | 1 |
| Alpert, JE | 1 |
| Birnbaum, RJ | 1 |
| Fava, M | 1 |
| McElroy, S | 1 |
| Walden, J | 2 |
| Kitchen, CM | 1 |
| Clayton, AH | 1 |
| Sachs, GS | 2 |
| Marangell, LB | 2 |
| Wisniewski, SR | 1 |
| Gyulai, L | 1 |
| Friedman, ES | 1 |
| Bowden, CL | 1 |
| Fossey, MD | 1 |
| Ostacher, MJ | 1 |
| Ketter, TA | 2 |
| Patel, J | 1 |
| Hauser, P | 1 |
| Rapport, D | 1 |
| Martinez, JM | 1 |
| Allen, MH | 1 |
| Miklowitz, DJ | 1 |
| Otto, MW | 1 |
| Dennehy, EB | 1 |
| Thase, ME | 1 |
| Shopsin, B | 2 |
| Zarate, CA | 1 |
| Tohen, M | 3 |
| Baraibar, G | 1 |
| Kando, JC | 1 |
| Mirin, J | 1 |
| Stoll, AL | 2 |
| Banov, M | 1 |
| Thibault, AB | 1 |
| Rosenbaum, JF | 1 |
| Mayer, PV | 1 |
| Kolbrener, M | 1 |
| Goldstein, E | 1 |
| Suplit, B | 1 |
| Lucier, J | 1 |
| Cohen, BM | 1 |
| Brown, ES | 1 |
| Dilsaver, SC | 1 |
| Shoaib, AM | 1 |
| Swann, AC | 1 |
| Kellner, CH | 1 |
| Pritchett, JT | 1 |
| Jackson, CW | 1 |
| Akiskal, HS | 2 |
| Oslin, DW | 1 |
| Duffy, K | 1 |
| Masand, P | 1 |
| Stern, TA | 1 |
| Popli, AP | 1 |
| Tanquary, J | 1 |
| Lamparella, V | 1 |
| Masand, PS | 1 |
| Balon, R | 1 |
| Jenkins, JB | 1 |
| Schroeder, DH | 1 |
| Pazzaglia, PJ | 1 |
| George, MS | 1 |
| Callahan, AM | 1 |
| Hinton, ML | 1 |
| Chao, J | 1 |
| Whitefield, SG | 1 |
| Lepage, JP | 1 |
| Gardos, G | 1 |
| Leibenluft, E | 1 |
| Frances, AJ | 1 |
| Kahn, DA | 1 |
| Carpenter, D | 1 |
| Docherty, JP | 1 |
| Donovan, SL | 1 |
| Schaller, JL | 1 |
| Behar, D | 1 |
| Spier, SA | 1 |
| Grossman, F | 1 |
| Potter, WZ | 1 |
| Brown, EA | 1 |
| Maislin, G | 1 |
| Filteau, MJ | 1 |
| Leblanc, J | 1 |
| Lefrançoise, S | 1 |
| Demers, MF | 1 |
| Amann, B | 1 |
| Hummel, B | 1 |
| Rall-Autenrieth, H | 1 |
| Compton, MT | 1 |
| Nemeroff, CB | 1 |
| Goren, JL | 1 |
| Levin, GM | 1 |
| Weintraub, D | 1 |
| Linder, MW | 1 |
| El-Mallakh, RS | 1 |
| Stadtland, C | 1 |
| Arolt, V | 1 |
| Gabbay, V | 1 |
| O'Dowd, MA | 1 |
| Asnis, GM | 1 |
| Fichtner, CG | 1 |
| Braun, BG | 1 |
| Fogelson, DL | 1 |
| Bystritsky, A | 1 |
| Pasnau, R | 1 |
| Ames, D | 1 |
| Wirshing, WC | 1 |
| Szuba, MP | 1 |
| Novac, A | 1 |
| Zubieta, JK | 1 |
| Demitrack, MA | 1 |
| Bittman, BJ | 1 |
| Young, RC | 1 |
| Haykal, RF | 1 |
| Jack, RA | 1 |
| Wright, G | 1 |
| Galloway, L | 1 |
| Kim, J | 1 |
| Dalton, M | 1 |
| Miller, L | 1 |
| Stern, W | 1 |
| Lerer, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study by 1H NMR of the Variations of the Metabolome During the Course of Electroconvulsive Therapy in Patients With Major Depressive Episode[NCT05973643] | 50 participants (Anticipated) | Interventional | 2023-10-15 | Not yet recruiting | |||
| The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy[NCT05450822] | 550 participants (Anticipated) | Observational | 2022-02-18 | Recruiting | |||
| Clinical Evaluation of the Antidepressant Effect of the Use of Probiotics in Bipolar Disorder and Possible Mediating Effects of Systemic and Intestinal Inflammatory Markers in the Microbiota[NCT05762887] | 84 participants (Anticipated) | Interventional | 2023-01-09 | Recruiting | |||
| Music as a Potential Intervention to Improve Hemodynamic Tolerability of Repetitive Sub-Anesthetic IV Ketamine Infusions in Bipolar and Unipolar Depression: A Pilot Study[NCT04701866] | 32 participants (Actual) | Interventional | 2021-01-11 | Completed | |||
| A Collaborative Treatment Network for Youth With or at High Risk for Bipolar Disorder[NCT05427123] | 80 participants (Anticipated) | Observational | 2022-07-01 | Recruiting | |||
| PRIME Care (PRecision Medicine In MEntal Health Care)[NCT03170362] | 1,944 participants (Actual) | Interventional | 2017-06-15 | Completed | |||
| A Phase 4, Randomized, Double-blind, Active And Placebo-controlled, Multicenter Study Evaluating The Neuropsychiatric Safety And Efficacy Of 12 Weeks Varenicline Tartrate 1mg Bid And Bupropion Hydrochloride 150mg Bid For Smoking Cessation In Subjects With[NCT01456936] | Phase 4 | 8,144 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)[NCT00012558] | 5,000 participants | Interventional | 1998-09-30 | Completed | |||
| Targeted Alterations in n-3 and n-6 Fatty Acids for the Management of Mood Variability in the Maintenance Phase of Bipolar Disorder[NCT02272010] | 83 participants (Actual) | Interventional | 2014-10-31 | Completed | |||
| Detailed Protocol: Evaluation of Transcranial Photobiomodulation for the Treatment of Pediatric Depression: An Open-Label Pilot Study[NCT04579185] | 30 participants (Anticipated) | Interventional | 2020-11-30 | Not yet recruiting | |||
| Accelerated Intermittent Theta-Burst Stimulation (aiTBS) in Treatment-Resistant Depression of Bipolar II Disorder[NCT05849402] | 60 participants (Anticipated) | Interventional | 2022-12-20 | Recruiting | |||
| An Exploratory Randomized Open Comparison of Oxtellar XR® vs Oxcarbazepine IR (Trileptal®) for the Treatment of Bipolar Depression[NCT03567681] | Phase 4 | 120 participants (Anticipated) | Interventional | 2018-06-13 | Enrolling by invitation | ||
| Acute Efficacy of Bupropion, Sertraline, and Venlafaxine as Adjuvant Treatment to Mood Stabilizers in Bipolar Depression: A Randomized, Double-Blind, Comparative Study[NCT00001483] | Phase 2 | 75 participants | Interventional | 1995-06-30 | Completed | ||
| Effect of Bupropion on Seizure Threshold in Depressed Patients[NCT03126682] | Phase 4 | 10 participants (Actual) | Interventional | 2017-08-25 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"A responder to this endpoint requires the answer no to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive)." (NCT01456936)
Timeframe: Week 9 through Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| Varenicline 1.0 mg BID | 33.5 |
| Bupropion 150 mg BID | 22.6 |
| NRT Patch | 23.4 |
| Placebo | 12.5 |
"A responder to this endpoint requires the answer no to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive)." (NCT01456936)
Timeframe: Week 9 through Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| Varenicline 1.0 mg BID | 38.0 |
| Bupropion 150 mg BID | 26.1 |
| NRT Patch | 26.4 |
| Placebo | 13.7 |
"A responder to this endpoint requires the answer no to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive)." (NCT01456936)
Timeframe: Week 9 through Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| Varenicline 1.0 mg BID | 29.2 |
| Bupropion 150 mg BID | 19.3 |
| NRT Patch | 20.4 |
| Placebo | 11.4 |
"A responder to this endpoint requires the answer no to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive)." (NCT01456936)
Timeframe: Week 9 through Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Varenicline 1.0 mg BID | 21.8 |
| Bupropion 150 mg BID | 16.2 |
| NRT Patch | 15.7 |
| Placebo | 9.4 |
"A responder to this endpoint requires the answer no to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive)." (NCT01456936)
Timeframe: Week 9 through Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Varenicline 1.0 mg BID | 25.5 |
| Bupropion 150 mg BID | 18.8 |
| NRT Patch | 18.5 |
| Placebo | 10.5 |
"A responder to this endpoint requires the answer no to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive)." (NCT01456936)
Timeframe: Week 9 through Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Varenicline 1.0 mg BID | 18.3 |
| Bupropion 150 mg BID | 13.7 |
| NRT Patch | 13.0 |
| Placebo | 8.3 |
"The CGI-I is a clinician rated instrument that measures change in participant's psychiatric condition (or lack thereof in the stratum without psychiatric disorders) on a 7 point scale ranging from 1 (very much improved) to 7 (very much worse), with 4 = no change. The ratings were applicable even to those without psychiatric diagnoses (eg, those with no psychiatric symptoms would be rated as normal, not at all ill on the CGI-S at baseline and assuming no psychiatric symptoms emerge during the trial, would be rated as no change on the CGI-I at follow-up visits). For those participants with a psychiatric diagnosis, the clinician should rate the severity of the mental illness with respect to the clinician's experience with the psychiatric population to which the participant belongs." (NCT01456936)
Timeframe: Baseline to Week 24
| Intervention | percentage of participants (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 (N= 1986, 1974, 1986, 1982) | Week 2 (N= 1934, 1936, 1927, 1926) | Week 3 (N= 1880, 1892, 1880, 1863) | Week 4 (N= 1860, 1856, 1858, 1834) | Week 5 (N= 1828, 1816, 1822, 1802) | Week 6 (N= 1816, 1808, 1820, 1773) | Week 8 (N= 1758, 1756, 1755, 1738) | Week 10 (N= 1717, 1707, 1715, 1675) | Week 12 (N= 1558, 1572, 1540, 1492) | Week 13 (N= 1612, 16081602, 1575) | Week 16 (N= 1586, 1606, 1568, 1541) | Week 20 (N= 1563, 1573, 1523, 1510) | Week 24 (N= 1533, 1515, 1499, 1497) | |
| Bupropion 150 mg BID | 93.2 | 90.8 | 89.8 | 88.0 | 86.5 | 86.5 | 83.6 | 81.7 | 75.1 | 76.7 | 76.7 | 75.0 | 72.3 |
| NRT Patch | 94.6 | 90.5 | 88.7 | 87.1 | 85.5 | 85.1 | 82.8 | 80.4 | 72.2 | 75.2 | 73.9 | 72.2 | 71.1 |
| Placebo | 95.1 | 91.2 | 87.9 | 86.3 | 85.4 | 84.1 | 81.9 | 79.2 | 71.3 | 74.9 | 73.4 | 71.7 | 71.1 |
| Varenicline 1.0 mg BID | 94.2 | 90.8 | 88.3 | 86.6 | 85.7 | 85.2 | 82.4 | 80.6 | 72.9 | 75.9 | 74.2 | 73.4 | 71.8 |
"A responder to this endpoint requires the answer no to both questions 3 and 6 on the nicotine use inventory at that specific visit.~NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?" (NCT01456936)
Timeframe: 24 Weeks
| Intervention | percentage of participants (Number) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 | Week 9 | Week 10 | Week 11 | Week 12 | Week 13 | Week 14 | Week 15 | Week 16 | Week 17 | Week 18 | Week 19 | Week 20 | Week 21 | Week 22 | Week 23 | Week 24 | |
| Bupropion 150 mg BID | 1.1 | 17.9 | 22.3 | 24.4 | 25.7 | 26.9 | 30.2 | 26.5 | 30.4 | 27.6 | 30.7 | 27.1 | 26.5 | 29.2 | 29.2 | 25.1 | 27.9 | 27.8 | 27.9 | 23.9 | 26.7 | 26.4 | 27.0 | 23.2 |
| NRT Patch | 0.9 | 14.2 | 20.0 | 23.5 | 25.1 | 26.8 | 31.3 | 28.0 | 32.1 | 28.0 | 32.1 | 27.6 | 26.9 | 29.4 | 29.2 | 24.9 | 28.1 | 28.2 | 28.1 | 23.7 | 26.5 | 26.3 | 25.3 | 23.6 |
| Placebo | 1.0 | 10.3 | 12.1 | 13.1 | 13.6 | 14.6 | 17.9 | 15.9 | 18.1 | 15.5 | 18.8 | 16.0 | 16.0 | 19.1 | 19.8 | 16.1 | 18.8 | 19.5 | 19.2 | 16.3 | 18.8 | 18.4 | 18.3 | 15.7 |
| Varenicline 1.0 mg BID | 1.3 | 18.8 | 26.3 | 30.4 | 33.4 | 35.8 | 39.5 | 37.4 | 41.6 | 38.7 | 42.5 | 39.6 | 36.8 | 39.5 | 38.5 | 33.1 | 36.4 | 36.2 | 35.7 | 30.8 | 33.9 | 33.8 | 33.0 | 29.8 |
"A responder to this endpoint requires the answer no to both questions 3 and 6 on the nicotine use inventory at that specific visit.~NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?" (NCT01456936)
Timeframe: 24 Weeks
| Intervention | percentage of participants (Number) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 | Week 9 | Week 10 | Week 11 | Week 12 | Week 13 | Week 14 | Week 15 | Week 16 | Week 17 | Week 18 | Week 19 | Week 20 | Week 21 | Week 22 | Week 23 | Week 24 | |
| Bupropion 150 mg BID | 1.0 | 21.3 | 26.6 | 27.7 | 29.8 | 31.4 | 35.2 | 31.0 | 34.9 | 31.0 | 34.1 | 30.5 | 30.7 | 33.5 | 33.2 | 28.5 | 31.9 | 31.3 | 31.2 | 27.5 | 30.3 | 29.9 | 30.6 | 26.0 |
| NRT Patch | 1.2 | 15.5 | 22.1 | 25.9 | 27.8 | 30.4 | 35.1 | 31.4 | 34.8 | 31.1 | 34.9 | 30.4 | 29.9 | 32.0 | 32.4 | 28.1 | 31.4 | 31.7 | 31.2 | 26.3 | 29.3 | 29.0 | 28.3 | 27.0 |
| Placebo | 1.5 | 11.4 | 13.6 | 14.5 | 14.9 | 15.9 | 19.2 | 16.7 | 19.0 | 16.9 | 20.8 | 17.8 | 17.2 | 20.4 | 21.3 | 18.2 | 20.1 | 20.8 | 20.8 | 18.2 | 20.1 | 20.3 | 20.3 | 17.4 |
| Varenicline 1.0 mg BID | 1.7 | 20.9 | 30.0 | 34.3 | 38.4 | 41.0 | 44.4 | 42.3 | 47.1 | 42.4 | 46.6 | 44.4 | 41.1 | 44.5 | 43.8 | 37.2 | 40.7 | 40.9 | 39.9 | 35.1 | 38.1 | 38.7 | 37.6 | 33.6 |
"A responder to this endpoint requires the answer no to both questions 3 and 6 on the nicotine use inventory at that specific visit.~NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?" (NCT01456936)
Timeframe: 24 Weeks
| Intervention | percentage of participants (Number) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 | Week 9 | Week 10 | Week 11 | Week 12 | Week 13 | Week 14 | Week 15 | Week 16 | Week 17 | Week 18 | Week 19 | Week 20 | Week 21 | Week 22 | Week 23 | Week 24 | |
| Bupropion 150 mg BID | 1.2 | 14.6 | 18.1 | 21.3 | 21.8 | 22.7 | 25.4 | 22.1 | 26.0 | 24.3 | 27.4 | 23.9 | 22.6 | 25.0 | 25.3 | 21.9 | 24.0 | 24.5 | 24.7 | 20.4 | 23.2 | 22.9 | 23.5 | 20.4 |
| NRT Patch | 0.7 | 13.0 | 17.9 | 21.1 | 22.4 | 23.3 | 27.5 | 24.6 | 29.4 | 25.0 | 29.4 | 24.9 | 24.0 | 26.8 | 26.0 | 21.8 | 24.8 | 24.7 | 25.1 | 25.1 | 23.7 | 23.6 | 22.2 | 20.1 |
| Placebo | 0.5 | 9.2 | 10.7 | 11.8 | 12.4 | 13.4 | 16.6 | 15.0 | 17.2 | 14.0 | 17.2 | 14.2 | 14.8 | 17.8 | 18.3 | 13.9 | 17.4 | 18.2 | 17.6 | 17.6 | 17.5 | 16.5 | 16.4 | 14.0 |
| Varenicline 1.0 mg BID | 1.0 | 16.8 | 22.7 | 26.6 | 28.5 | 30.8 | 34.8 | 32.7 | 36.2 | 35.1 | 38.6 | 35.0 | 32.7 | 34.7 | 33.4 | 29.1 | 32.3 | 31.7 | 31.6 | 26.6 | 29.7 | 29.1 | 28.5 | 26.1 |
"The primary safety endpoint is the occurrence of at least one treatment emergent severe adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent moderate or severe adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Estimated NPS AE rate (%) was calculated based on least-squares means analysis." (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
| Intervention | percentage of participants (Least Squares Mean) | |
|---|---|---|
| Non-psychiatric cohort (N=3984) | Psychiatric cohort (N= 4074) | |
| Bupropion 150 mg BID | 2.44 | 6.62 |
| NRT Patch | 2.31 | 5.20 |
| Placebo | 2.52 | 4.83 |
| Varenicline 1.0 mg BID | 1.25 | 6.42 |
The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms. (NCT01456936)
Timeframe: Baseline to Week 24
| Intervention | Units on a scale (Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 (N= 1989, 1976, 1985, 1987) | Week 2 (N= 1938, 1937, 1931, 1929) | Week 3 (N= 1882, 1891, 1881, 1867) | Week 4 (N= 1858, 1854, 1863, 1831) | Week 5 (N= 1829, 1815, 1820, 1797) | Week 6 (N= 1816, 1807, 1821, 1771) | Week 8 (N= 1755, 1754, 1755, 1736) | Week 10 (N= 1717, 1709, 1716, 1669) | Week 12 (N= 1562, 1571, 1548, 1491) | Week 13 (N= 1610, 1608, 1603, 1570) | Week 16 (N= 1579, 1602, 1566, 1537) | Week 20 (N= 1555, 1569, 1525, 1509) | Week 24 (N= 1528, 1512, 1495, 1487) | |
| Bupropion 150 mg BID | 5.61 | 5.06 | 4.60 | 4.39 | 4.16 | 4.05 | 4.10 | 3.86 | 3.79 | 3.66 | 3.77 | 3.73 | 3.80 |
| NRT Patch | 4.95 | 4.74 | 4.48 | 4.31 | 4.08 | 4.01 | 3.96 | 4.00 | 3.78 | 3.71 | 3.78 | 3.72 | 3.82 |
| Placebo | 5.05 | 4.80 | 4.38 | 4.39 | 4.14 | 4.09 | 4.12 | 4.04 | 3.95 | 3.70 | 3.82 | 3.75 | 3.62 |
| Varenicline 1.0 mg BID | 5.03 | 4.68 | 4.31 | 4.15 | 3.94 | 3.82 | 3.82 | 3.85 | 3.64 | 3.60 | 3.67 | 3.65 | 3.62 |
The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms. (NCT01456936)
Timeframe: Baseline to Week 24
| Intervention | Units on a scale (Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 (N= 1026, 1017, 1015, 1015) | Week 2 (N= 1005, 1004, 996, 995) | Week 3 (N= 947, 961, 945, 926) | Week 4 (N= 935, 938, 929, 908) | Week 5 (N= 918, 918, 914, 895) | Week 6 (N= 917, 914, 912, 874) | Week 8 (N= 887, 893, 878, 859) | Week 10 (N= 864, 865, 864, 823) | Week 12 (N= 790, 803, 798, 749) | Week 13 (N= 813, 812, 814, 763) | Week 16 (N= 795, 805, 791, 748) | Week 20 (N= 784, 784, 763, 737) | Week 24 (N= 770, 764, 758, 729) | |
| Bupropion 150 mg BID | 7.58 | 6.99 | 6.51 | 6.36 | 6.03 | 5.87 | 5.96 | 5.72 | 5.66 | 5.44 | 5.62 | 5.54 | 5.69 |
| NRT Patch | 6.82 | 6.64 | 6.30 | 6.16 | 5.82 | 5.62 | 5.63 | 5.64 | 5.44 | 5.36 | 5.44 | 5.46 | 5.57 |
| Placebo | 6.70 | 6.42 | 6.02 | 6.04 | 5.80 | 5.75 | 5.63 | 5.55 | 5.42 | 5.09 | 5.37 | 5.26 | 5.04 |
| Varenicline 1.0 mg BID | 6.76 | 6.42 | 5.99 | 5.87 | 5.58 | 5.39 | 5.43 | 5.38 | 5.17 | 5.06 | 5.26 | 5.17 | 5.21 |
The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms. (NCT01456936)
Timeframe: Baseline to Week 24
| Intervention | Units on a scale (Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 (N= 984, 972, 989, 992) | Week 2 (N= 961, 954, 963, 970) | Week 3 (N= 935, 930, 936, 941) | Week 4 (N= 923, 916, 934, 923) | Week 5 (N= 911, 897, 906, 902) | Week 6 (N= 899, 893, 909, 897) | Week 8 (N= 868, 861, 877, 877) | Week 10 (N= 853, 844, 852, 846) | Week 12 (N= 772, 768, 750, 742) | Week 13 (N= 797, 796, 789, 807) | Week 16 (N= 784, 797, 775, 789) | Week 20 (N= 771, 785, 762, 772) | Week 24 (N= 758, 748, 737, 758) | |
| Bupropion 150 mg BID | 3.58 | 3.07 | 2.64 | 2.36 | 2.24 | 2.18 | 2.16 | 1.96 | 1.83 | 1.85 | 1.90 | 1.93 | 1.87 |
| NRT Patch | 3.06 | 2.84 | 2.63 | 2.46 | 2.32 | 2.40 | 2.28 | 2.33 | 2.01 | 2.01 | 2.09 | 1.97 | 2.01 |
| Placebo | 3.38 | 3.20 | 2.77 | 2.77 | 2.48 | 2.48 | 2.64 | 2.57 | 2.46 | 2.38 | 2.34 | 2.31 | 2.25 |
| Varenicline 1.0 mg BID | 3.26 | 2.91 | 2.61 | 2.40 | 2.29 | 2.23 | 2.17 | 2.29 | 2.07 | 2.11 | 2.05 | 2.10 | 2.01 |
"The primary safety endpoint is the occurrence of at least one treatment emergent severe adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent moderate or severe adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide." (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Non-psychiatric cohort (N= 990, 989, 1006, 999) | Psychiatric cohort (N= 1026, 1017, 1016, 1015) | Overall (N= 2016, 2006, 2022, 2014) | |
| Bupropion 150 mg BID | 2.2 | 6.7 | 4.5 |
| NRT Patch | 2.5 | 5.2 | 3.9 |
| Placebo | 2.4 | 4.9 | 3.7 |
| Varenicline 1.0 mg BID | 1.3 | 6.5 | 4.0 |
"The primary safety endpoint is the occurrence of at least one treatment emergent severe adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent moderate or severe adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint." (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Non-psychiatric cohort (N= 990, 989, 1006, 999) | Psychiatric cohort (N= 1026, 1017, 1016, 1015) | Overall (N= 2016, 2006, 2022, 2014) | |
| Bupropion 150 mg BID | 0.4 | 1.4 | 0.9 |
| NRT Patch | 0.3 | 1.4 | 0.8 |
| Placebo | 0.5 | 1.3 | 0.9 |
| Varenicline 1.0 mg BID | 0.1 | 1.4 | 0.7 |
The NPS AE composite results (as previously described) are for the two cohorts combined and are presented below. (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anxiety | Depression | Feeling Abnormal | Hostility | Agitation | Aggression | Delusions | Hallucination | Mania | Panic Disorder | Paranoia | Psychosis | Homicidal Ideation | Suicidal Behavior | Suicidal Ideation | Suicide | |
| Bupropion 150 mg BID | 5 | 4 | 1 | 1 | 40 | 12 | 1 | 4 | 10 | 20 | 1 | 2 | 0 | 2 | 3 | 0 |
| NRT Patch | 6 | 7 | 0 | 1 | 40 | 9 | 2 | 2 | 5 | 14 | 0 | 4 | 1 | 1 | 5 | 0 |
| Placebo | 5 | 6 | 0 | 0 | 33 | 11 | 0 | 2 | 8 | 10 | 2 | 1 | 0 | 1 | 5 | 1 |
| Varenicline 1.0 mg BID | 5 | 7 | 0 | 0 | 35 | 17 | 1 | 6 | 7 | 7 | 1 | 4 | 0 | 1 | 5 | 0 |
"The NPS AE endpoint was the occurrence of at least 1 treatment-emergent severe AE of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least 1 treatment-emergent severe AE of agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint." (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anxiety | Depression | Feeling Abnormal | Hostility | Agitation | Aggression | Delusions | Hallucination | Mania | Panic Disorder | Paranoia | Psychosis | Suicidal Behavior | Suicidal Ideation | Suicide | Homicidal Ideation | |
| Bupropion 150 mg BID | 5 | 4 | 1 | 1 | 1 | 2 | 0 | 1 | 1 | 2 | 1 | 2 | 2 | 0 | 0 | 0 |
| NRT Patch | 6 | 7 | 0 | 1 | 6 | 0 | 0 | 0 | 0 | 1 | 0 | 4 | 0 | 1 | 0 | 1 |
| Placebo | 5 | 6 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 2 | 2 | 1 | 1 | 0 | 1 | 0 |
| Varenicline 1.0 mg BID | 5 | 7 | 0 | 0 | 1 | 2 | 0 | 0 | 2 | 0 | 1 | 4 | 1 | 1 | 0 | 0 |
"The safety endpoint is the occurrence of at least one treatment emergent severe adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent moderate or severe adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Each of these 16 components is reported below." (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anxiety (severe) | Depression (severe) | Feeling abnormal (severe only) | Hostility (severe) | Agitation (moderate and severe) | Aggression (moderate and severe) | Delusions (moderate and severe) | Hallucinations (moderate and severe) | Mania (moderate and severe) | Panic (moderate and severe) | Paranoia (moderate and severe) | Psychosis (moderate and severe) | Homicidal ideation (moderate and severe) | Suicidal behavior (moderate and severe) | Suicidal ideation (moderate and severe) | Suicide (moderate and severe) | |
| Bupropion 150 mg BID | 1 | 0 | 0 | 1 | 11 | 3 | 0 | 0 | 1 | 4 | 1 | 0 | 0 | 1 | 1 | 0 |
| NRT Patch | 0 | 0 | 0 | 1 | 19 | 2 | 1 | 0 | 2 | 1 | 0 | 1 | 1 | 1 | 2 | 0 |
| Placebo | 3 | 0 | 0 | 0 | 11 | 3 | 0 | 0 | 2 | 3 | 0 | 0 | 0 | 0 | 3 | 1 |
| Varenicline 1.0 mg BID | 0 | 1 | 0 | 0 | 10 | 3 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
"The safety endpoint is the occurrence of at least one treatment emergent severe adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent moderate or severe adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Each of these 16 components is reported below." (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anxiety (severe) | Depression (severe) | Feeling abnormal (severe only) | Hostility (severe) | Agitation (moderate and severe) | Aggression (moderate and severe) | Delusions (moderate and severe) | Hallucinations (moderate and severe) | Mania (moderate and severe) | Panic (moderate and severe) | Paranoia (moderate and severe) | Psychosis (moderate and severe) | Homicidal ideation (moderate and severe) | Suicidal behavior (moderate and severe) | Suicidal ideation (moderate and severe) | Suicide (moderate and severe) | |
| Bupropion 150 mg BID | 4 | 4 | 1 | 0 | 29 | 9 | 1 | 4 | 9 | 16 | 0 | 2 | 0 | 1 | 2 | 0 |
| NRT Patch | 6 | 7 | 0 | 0 | 21 | 7 | 1 | 2 | 3 | 13 | 0 | 3 | 0 | 0 | 3 | 0 |
| Placebo | 2 | 6 | 0 | 0 | 22 | 8 | 0 | 2 | 6 | 7 | 2 | 1 | 0 | 1 | 2 | 0 |
| Varenicline 1.0 mg BID | 5 | 6 | 0 | 0 | 25 | 14 | 1 | 5 | 7 | 7 | 1 | 4 | 0 | 1 | 5 | 0 |
"The safety endpoint is the occurrence of at least one treatment emergent severe adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent moderate or severe adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint." (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anxiety | Depression | Feeling abnormal | Hostility | Agitation | Aggression | Delusions | Hallucinations | Mania | Panic | Paranoia | Psychosis | Homicidal ideation | Suicidal behavior | Suicidal ideation | Suicide | |
| Bupropion 150 mg BID | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| NRT Patch | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 |
| Varenicline 1.0 mg BID | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
"The safety endpoint is the occurrence of at least one treatment emergent severe adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent moderate or severe adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint." (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anxiety | Depression | Feeling abnormal | Hostility | Agitation | Aggression | Delusions | Hallucinations | Mania | Panic | Paranoia | Psychosis | Homicidal ideation | Suicidal behavior | Suicidal ideation | Suicide | |
| Bupropion 150 mg BID | 4 | 4 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 |
| NRT Patch | 6 | 7 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Placebo | 2 | 6 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Varenicline 1.0 mg BID | 5 | 6 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
"The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from wish to be dead to active suicidal ideation with specific plan and intent. Answers at screening are for lifetime history. Answers for all other visits are since last visit.The scale is also used to record any completed suicides." (NCT01456936)
Timeframe: Lifetime, Baseline and Treatment-Emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
| Intervention | participants with positive responses (Number) | |||||
|---|---|---|---|---|---|---|
| Suicidal Behavior (Screening lifetime) | Suicidal Ideation (Screening lifetime) | Suicidal Behavior (Baseline) | Suicidal Ideation (Baseline) | Suicidal Behavior (treatment emergent 12 weeks) | Suicidal Ideation (treatment emergent 12 weeks) | |
| Bupropion 150 mg BID | 9 | 43 | 0 | 1 | 0 | 4 |
| NRT Patch | 7 | 50 | 0 | 0 | 1 | 3 |
| Placebo | 6 | 49 | 0 | 1 | 1 | 6 |
| Varenicline 1.0 mg BID | 6 | 48 | 0 | 0 | 0 | 7 |
"The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from wish to be dead to active suicidal ideation with specific plan and intent. Answers at screening are for lifetime history. Answers for all other visits are since last visit. The scale is also used to record any completed suicides." (NCT01456936)
Timeframe: Lifetime, Baseline and Treatment-Emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
| Intervention | participants with positive responses (Number) | |||||
|---|---|---|---|---|---|---|
| Suicidal Behavior (Screening lifetime) | Suicidal Ideation (Screening lifetime) | Suicidal Behavior (Baseline) | Suicidal Ideation (Baseline) | Suicidal Behavior (treatment emergent 12 weeks) | Suicidal Ideation (treatment emergent 12 weeks) | |
| Bupropion 150 mg BID | 152 | 400 | 0 | 6 | 1 | 19 |
| NRT Patch | 118 | 383 | 0 | 2 | 1 | 23 |
| Placebo | 129 | 398 | 1 | 4 | 3 | 31 |
| Varenicline 1.0 mg BID | 143 | 386 | 0 | 6 | 0 | 34 |
"The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from wish to be dead to active suicidal ideation with specific plan and intent. Answers at screening are for lifetime history. Answers for all other visits are since last visit. The scale is also used to record any completed suicides." (NCT01456936)
Timeframe: Lifetime, Baseline and Treatment-Emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
| Intervention | participants with positive responses (Number) | |||||
|---|---|---|---|---|---|---|
| Suicidal Behavior (Screening lifetime) | Suicidal Ideation (Screening lifetime) | Suicidal Behavior (Baseline) | Suicidal Ideation (Baseline) | Suicidal Behavior (treatment emergent 12 weeks) | Suicidal Ideation (treatment emergent 12 weeks) | |
| Bupropion 150 mg BID | 143 | 357 | 0 | 5 | 1 | 15 |
| NRT Patch | 111 | 333 | 0 | 2 | 0 | 20 |
| Placebo | 123 | 349 | 1 | 3 | 2 | 25 |
| Varenicline 1.0 mg BID | 137 | 338 | 0 | 6 | 0 | 27 |
Scoring of depressive symptoms on the Montgomery Asberg Depression Rating Scale, maximum 60 , minimum 0. Higher scores mean worse outcome. First measurement on day 1 of electroconvulsive treatment (ECT) and second measurement on day 2 of electroconvulsive therapy (ECT), separated by 1 day interval. This outcome measure was not measured at baseline. (NCT03126682)
Timeframe: Scored on day 1 and day 2 after ECT session
| Intervention | Scored on a scale (Mean) |
|---|---|
| Wellbutrin During ECT 1 | 2.60 |
| Wellbutrin During ECT 2 | 3.60 |
Duration of seizures with ECT. First measurement on day 1 of electroconvulsive treatment (ECT) and second measurement on day 2 of electroconvulsive therapy (ECT), separated by 1 day interval. This outcome measure was not measured at baseline. (NCT03126682)
Timeframe: Measured at day 1 and day 2
| Intervention | seconds (Mean) |
|---|---|
| Wellbutrin During ECT 1 | 26.2 |
| Wellbutrin During ECT 2 | 29.6 |
Charge in Millicoulombs at which subject gets a seizure with ECT. First measurement on day 1 of electroconvulsive treatment (ECT) and second measurement on day 2 of electroconvulsive therapy (ECT), separated by 1 day interval. This outcome measure was not measured at baseline. (NCT03126682)
Timeframe: Measured at day 1 and day 2
| Intervention | millicoulombs (Mean) |
|---|---|
| Wellbutrin During ECT 1 | 23.04 |
| Wellbutrin During ECT 2 | 19.68 |
13 reviews available for bupropion and Bipolar Disorder
| Article | Year |
|---|---|
Combinations of dextromethorphan for the treatment of mood disorders - a review of the evidence.
Topics: Adult; Bipolar Disorder; Bupropion; Depressive Disorder, Major; Depressive Disorder, Treatment-Resis | 2023 |
Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials.
Topics: Adult; Animals; Antidepressive Agents; Bipolar Disorder; Bupropion; Depressive Disorder, Major; Dext | 2021 |
Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review.
Topics: Behavior Therapy; Bipolar Disorder; Bupropion; Cardiovascular Diseases; Diabetes Mellitus; Dopamine | 2016 |
Smoking cessation and reduction in people with chronic mental illness.
Topics: Anxiety Disorders; Bipolar Disorder; Bupropion; Electronic Nicotine Delivery Systems; Humans; Mental | 2015 |
Significant Treatment Effect of Bupropion in Patients With Bipolar Disorder but Similar Phase-Shifting Rate as Other Antidepressants: A Meta-Analysis Following the PRISMA Guidelines.
Topics: Antidepressive Agents; Bipolar Disorder; Bupropion; Humans; Severity of Illness Index | 2016 |
Topiramate for acute affective episodes in bipolar disorder.
Topics: Affective Disorders, Psychotic; Antimanic Agents; Bipolar Disorder; Bupropion; Depressive Disorder; | 2006 |
Extended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity?
Topics: Antidepressive Agents, Second-Generation; Bipolar Disorder; Bupropion; Delayed-Action Preparations; | 2007 |
Dysthymic and cyclothymic depressions: therapeutic considerations.
Topics: Adolescent; Adult; Antidepressive Agents, Tricyclic; Bipolar Disorder; Bupropion; Child; Combined Mo | 1994 |
Bupropion and secondary mania. Is there a relationship?
Topics: Adult; Bipolar Disorder; Bupropion; Depressive Disorder; Drug Therapy, Combination; Female; Humans; | 1993 |
Issues in the treatment of women with bipolar illness.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bipolar Disorder; Buprop | 1997 |
The treatment of bipolar depression.
Topics: Anticonvulsants; Antidepressive Agents; Bipolar Disorder; Bupropion; Combined Modality Therapy; Elec | 2000 |
Bupropion as add-on strategy in difficult-to-treat bipolar depressive patients.
Topics: Antidepressive Agents, Second-Generation; Bipolar Disorder; Bupropion; Clinical Trials as Topic; Dru | 2002 |
Alternative therapies for bipolar disorder.
Topics: Ascorbic Acid; Bipolar Disorder; Bupropion; Carbamazepine; Choline; Clonazepam; Clonidine; Clorgylin | 1985 |
19 trials available for bupropion and Bipolar Disorder
| Article | Year |
|---|---|
Duration of Adjunctive Antidepressant Maintenance in Bipolar I Depression.
Topics: Antidepressive Agents; Bipolar Disorder; Bupropion; Canada; Depression; Double-Blind Method; Escital | 2023 |
Do baseline sub-threshold hypomanic symptoms affect acute-phase antidepressant outcome in outpatients with major depressive disorder? Preliminary findings from the randomized CO-MED trial.
Topics: Adult; Ambulatory Care; Antidepressive Agents; Bipolar Disorder; Bupropion; Citalopram; Depressive D | 2018 |
Safety and efficacy of first-line smoking cessation pharmacotherapies in bipolar disorders: Subgroup analysis of a randomized clinical trial.
Topics: Bipolar Disorder; Bupropion; Counseling; Female; Humans; Male; Middle Aged; Nicotinic Agonists; Rand | 2019 |
Antidepressant dose and treatment response in bipolar depression: Reanalysis of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) data.
Topics: Adult; Antidepressive Agents, Second-Generation; Antimanic Agents; Antipsychotic Agents; Bipolar Dis | 2015 |
A preliminary study of sustained-release bupropion for smoking cessation in bipolar disorder.
Topics: Antidepressive Agents, Second-Generation; Bipolar Disorder; Bupropion; Delayed-Action Preparations; | 2008 |
Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study.
Topics: Acute Disease; Adult; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Bupropion; Cyclohex | 2009 |
Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study.
Topics: Acute Disease; Adult; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Bupropion; Depressive Dis | 2002 |
Combination pharmacotherapy in children and adolescents with bipolar disorder.
Topics: Adolescent; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Attention Deficit Disorde | 2003 |
An open trial of bupropion for the treatment of adults with attention-deficit/hyperactivity disorder and bipolar disorder.
Topics: Adult; Affect; Antidepressive Agents, Second-Generation; Attention Deficit Disorder with Hyperactivi | 2003 |
Hyponatremia associated with bupropion, a case verified by rechallenge.
Topics: Alcoholism; Antidepressive Agents, Second-Generation; Bipolar Disorder; Bupropion; Cocaine-Related D | 2005 |
Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Bupropion; Co | 2006 |
Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Bupropion; Co | 2006 |
Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Bupropion; Co | 2006 |
Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Bupropion; Co | 2006 |
Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline.
Topics: Adjuvants, Pharmaceutic; Adult; Affect; Antidepressive Agents; Antidepressive Agents, Second-Generat | 2006 |
Effectiveness of adjunctive antidepressant treatment for bipolar depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Antimanic Agents; Bipolar Disorder; Bupropion; Doub | 2007 |
Effectiveness of adjunctive antidepressant treatment for bipolar depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Antimanic Agents; Bipolar Disorder; Bupropion; Doub | 2007 |
Effectiveness of adjunctive antidepressant treatment for bipolar depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Antimanic Agents; Bipolar Disorder; Bupropion; Doub | 2007 |
Effectiveness of adjunctive antidepressant treatment for bipolar depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Antimanic Agents; Bipolar Disorder; Bupropion; Doub | 2007 |
Bupropion: a new clinical profile in the psychobiology of depression.
Topics: Antidepressive Agents; Bipolar Disorder; Body Weight; Bupropion; Clinical Trials as Topic; Depressiv | 1983 |
A double-blind trial of bupropion versus desipramine for bipolar depression.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Bupropion; Desipramine; Double-Blind Method; Drug Therapy, | 1994 |
Carbamazepine but not valproate induces bupropion metabolism.
Topics: Adult; Antidepressive Agents; Biotransformation; Bipolar Disorder; Bupropion; Carbamazepine; Cytochr | 1995 |
A double-blind study comparing idazoxan and bupropion in bipolar depressed patients.
Topics: Adrenergic alpha-Antagonists; Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Bup | 1999 |
Bupropion in the treatment of bipolar disorders: the same old story?
Topics: Adult; Aged; Ambulatory Care; Antidepressive Agents; Bipolar Disorder; Bupropion; Drug Therapy, Comb | 1992 |
Bupropion in the long-term treatment of cyclic mood disorders: mood stabilizing effects.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Body Weight; Bupropion; Chroni | 1985 |
55 other studies available for bupropion and Bipolar Disorder
| Article | Year |
|---|---|
[Manic Shift Due to the Use of Bupropion in Bipolar Depression:Two Case Reports].
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bipolar Disorder; Bupropion; | 2019 |
Why the Maternal Medication List Matters: Neonatal Toxicity From Combined Serotonergic Exposures.
Topics: Antidepressive Agents; Bipolar Disorder; Brain Diseases; Bupropion; Drug Therapy, Combination; Dyski | 2021 |
Bupropion-Induced Dyskinesia in a Young Adult Patient With Bipolar Disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Bupropion; Dyskinesia, Drug-Induc | 2017 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Antidepressant Prescription Patterns in Bipolar Disorder: a Nationwide, Register-based Study in Korea.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Anxiety Disor | 2018 |
Delirium caused by a drug-drug interaction between bupropion and risperidone.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bipolar Disorder; Bupropion; Citalop | 2014 |
A case of hypomania during nicotine cessation treatment with bupropion.
Topics: Aged; Antidepressive Agents, Second-Generation; Bipolar Disorder; Bupropion; Dysthymic Disorder; Hum | 2013 |
Effectiveness of a multi-component Smoking Cessation Support Programme (McSCSP) for patients with severe mental disorders: study design.
Topics: Antidepressive Agents, Second-Generation; Benzazepines; Bipolar Disorder; Bupropion; Clinical Trials | 2013 |
Frontotemporal dementia mimicking bipolar affective disorder, normal pressure hydrocephalus and Klüver-Bucy syndrome.
Topics: Antidepressive Agents, Second-Generation; Bipolar Disorder; Bupropion; Diagnosis, Differential; Elec | 2015 |
Bupropion abuse resulting in hypomania in a geriatric amphetamine user: A case report.
Topics: Aged; Amphetamine-Related Disorders; Antidepressive Agents, Second-Generation; Bipolar Disorder; Bup | 2015 |
Clinical Experience With High-Dosage Pramipexole in Patients With Treatment-Resistant Depressive Episodes in Unipolar and Bipolar Depression.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Benzothiazoles; Bipolar Disorder; Bupropion; | 2016 |
Bupropion-induced hypomania in a patient with unipolar depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Bupropion; Depressive Disorder; D | 2008 |
Smoking cessation: the psychiatrist's role.
Topics: Antimanic Agents; Benzazepines; Bipolar Disorder; Bupropion; Humans; Lithium Carbonate; Psychiatry; | 2008 |
Chronic imipramine but not bupropion increases arachidonic acid signaling in rat brain: is this related to 'switching' in bipolar disorder?
Topics: Animals; Arachidonic Acid; Bipolar Disorder; Bupropion; Cyclooxygenase 1; Cyclooxygenase 2; Dinopros | 2010 |
Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression.
Topics: Adolescent; Adult; Affect; Aged; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Bupropio | 2009 |
A 51-year-old woman with bipolar disorder who wants to quit smoking.
Topics: Benzazepines; Bipolar Disorder; Bupropion; Counseling; Female; Humans; Middle Aged; Quinoxalines; Sm | 2009 |
Antidepressant treatment and smoking cessation in bipolar disorder.
Topics: Antidepressive Agents, Second-Generation; Bipolar Disorder; Bupropion; Contraindications; Humans; Ri | 2009 |
Low-dose buspirone, melatonin and low-dose bupropion added to mood stabilizers for severe treatment-resistant bipolar depression.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Bupropion; Buspirone; Drug Therapy, Combination; Fem | 2009 |
Use of the D2/D3 receptor agonist pramipexole in treatment of rapid-cycling bipolar disorder in an elderly patient.
Topics: Aged; Anticonvulsants; Antidepressive Agents, Second-Generation; Benzothiazoles; Bipolar Disorder; B | 2010 |
Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).
Topics: Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety Disorders; | 2010 |
Use of antidepressants during pregnancy and risk of attention-deficit/hyperactivity disorder in the offspring.
Topics: Adult; Antidepressive Agents, Second-Generation; Attention Deficit Disorder with Hyperactivity; Bipo | 2010 |
Bipolar disorder--a focus on depression.
Topics: Antidepressive Agents, Second-Generation; Bipolar Disorder; Bupropion; Humans; Phototherapy; Seasona | 2011 |
Bupropion-induced mania and hypomania: a report of two cases.
Topics: Adult; Bipolar Disorder; Bupropion; Humans; Male | 2011 |
Serum bupropion levels in 2 breastfeeding mother-infant pairs.
Topics: Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Breast Feeding; Bupropion; Depres | 2002 |
Hypomania induced by adjunctive lamotrigine.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Bupropion; Depressive Disorder, Major; Dose-Response | 2003 |
Suicide in pregnancy.
Topics: Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Bupropion; Female; Humans; Pregna | 2003 |
A case report of mania related to discontinuation of bupropion therapy for smoking cessation.
Topics: Acute Disease; Adult; Antidepressive Agents; Bipolar Disorder; Bupropion; Delusions; Female; Humans; | 2004 |
Treating depression in a mother of five: what to do when the first step fails.
Topics: Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Bupropion; Depressive Disorder, M | 2005 |
A survey of antidepressant prescribing practices in major depression with comorbid attention-deficit hyperactivity disorder.
Topics: Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Bupropion; C | 2006 |
Bupropion's prophylactic efficacy in bipolar affective illness.
Topics: Acute Disease; Adult; Antidepressive Agents; Bipolar Disorder; Bupropion; Drug Administration Schedu | 1983 |
Prescribing trends of antidepressants in bipolar depression.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Bupropion; Combined Modality Therapy; Drug Prescript | 1995 |
Antidepressant-associated mania: a controlled comparison with spontaneous mania.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Antidepressive Agents, Tricyclic; Bipolar Dis | 1994 |
Depressive mania: response of residual depression to bupropion.
Topics: Adult; Bipolar Disorder; Bupropion; Depressive Disorder; Drug Therapy, Combination; Female; Humans; | 1994 |
Bupropion coadministration with electroconvulsive therapy: two case reports.
Topics: Adult; Bipolar Disorder; Bupropion; Combined Modality Therapy; Depressive Disorder; Electroconvulsiv | 1994 |
The rise of serum aminotransferases in a patient treated with bupropion.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Bipolar Disorder; Bupropion; Chemical and D | 1993 |
Bupropion and anticonvulsant drug interactions.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Bipolar Disorder; Bupropion; Carbamazepine; Dose-Resp | 1995 |
Bupropion and nightmares.
Topics: Antidepressive Agents, Second-Generation; Bipolar Disorder; Bupropion; Dreams; Female; Humans; Middl | 1996 |
Treatment of bipolar disorder.
Topics: Antidepressive Agents; Bipolar Disorder; Bupropion; Humans; Treatment Outcome | 1996 |
Reversible dyskinesia during bupropion therapy.
Topics: Aged; Antidepressive Agents, Second-Generation; Bipolar Disorder; Bupropion; Dose-Response Relations | 1997 |
The Expert Consensus Guidelines for treating depression in bipolar disorder.
Topics: Algorithms; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Bupropion; Confidence Int | 1998 |
Treatment of a case of comorbid bipolar disorder and attention-deficit/hyperactivity disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Antimanic Agents; Attention Deficit Disorder with H | 1998 |
Use of bupropion with SRIs and venlafaxine.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Bipolar Disorder; Bupropion; Cyclohexanols; D | 1998 |
Visual and auditory hallucinations with the association of bupropion and valproate.
Topics: Anticonvulsants; Antidepressive Agents; Bipolar Disorder; Bupropion; Hallucinations; Humans; Male; M | 2000 |
Bupropion-induced isolated impairment of sensory trigeminal nerve function.
Topics: Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Bupropion; Female; Humans; Trigem | 2000 |
Mania with bupropion: a dose-related phenomenon?
Topics: Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Bupropion; Dose-Response Relation | 2000 |
Amphetamine positive toxicology screen secondary to bupropion.
Topics: Aged; Amphetamine; Antidepressive Agents, Second-Generation; Bipolar Disorder; Bupropion; Chromatogr | 2000 |
Bupropion manic induction during euthymia, but not during depression.
Topics: Bipolar Disorder; Bupropion; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Humans; M | 2001 |
Combined antidepressant treatment: a risk factor for switching in bipolar patients.
Topics: Anticonvulsants; Antidepressive Agents; Bipolar Disorder; Bupropion; Carbamazepine; Drug Administrat | 2002 |
Bupropion-associated mania in a patient with HIV infection.
Topics: Bipolar Disorder; Bupropion; Depressive Disorder; HIV Seropositivity; Humans; Male; Middle Aged | 1992 |
Organic mental disorders associated with bupropion in three patients.
Topics: Adult; Antidepressive Agents; Auditory Perceptual Disorders; Bipolar Disorder; Bupropion; Depressive | 1992 |
Fluoxetine and bupropion treatment of bipolar disorder, type II, associated with GAD.
Topics: Anxiety Disorders; Bipolar Disorder; Bupropion; Drug Therapy, Combination; Fluoxetine; Humans; Infan | 1992 |
Possible bupropion precipitation of mania and a mixed affective state.
Topics: Adult; Bipolar Disorder; Bupropion; Drug Therapy, Combination; Female; Humans; Lithium Carbonate | 1991 |
Mania in an elderly man treated with bupropion.
Topics: Aged; Antidepressive Agents; Bipolar Disorder; Bupropion; Depressive Disorder; Humans; Male; Propiop | 1991 |
Bupropion as a promising approach to rapid cycling bipolar II patients.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Bupropion; Carbamazepine; Clinical Protocols; Drug T | 1990 |
A case of mania secondary to propafenone.
Topics: Adult; Anti-Arrhythmia Agents; Bipolar Disorder; Bupropion; Cardiac Complexes, Premature; Female; Hu | 1985 |